NASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $84.05 +0.40 (+0.48%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$83.17▼$85.1450-Day Range$67.92▼$85.1652-Week Range$44.20▼$87.71Volume554,441 shsAverage Volume788,046 shsMarket Capitalization$9.14 billionP/E RatioN/ADividend YieldN/APrice Target$78.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vaxcyte alerts: Email Address Vaxcyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside6.6% Downside$78.50 Price TargetShort InterestBearish10.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.70Based on 12 Articles This WeekInsider TradingSelling Shares$7.92 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.93) to ($4.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 starsMedical Sector912th out of 936 stocksBiological Products, Except Diagnostic Industry149th out of 154 stocks 1.5 Analyst's Opinion Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has only been the subject of 2 research reports in the past 90 days.Read more about Vaxcyte's stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted10.91% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently increased by 15.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCVX. Previous Next 2.6 News and Social Media Coverage News SentimentVaxcyte has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Vaxcyte this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for PCVX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,923,441.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($3.93) to ($4.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -19.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -19.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 6.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vaxcyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About Vaxcyte Stock (NASDAQ:PCVX)Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More PCVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCVX Stock News HeadlinesJuly 26 at 5:16 AM | insidertrades.comGrant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockJuly 25 at 6:17 AM | insidertrades.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells 15,000 Shares of StockJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.July 23 at 4:05 AM | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 SharesJuly 18, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) SVP Sells $425,000.00 in StockJuly 10, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) SVP Sells $400,000.00 in StockJuly 3, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) SVP Mikhail Eydelman Sells 1,667 SharesJuly 3, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $199,679.28 in StockJuly 26, 2024 | Weiss Ratings (Ad)Nvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.June 26, 2024 | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering Sells 15,000 SharesJuly 24 at 1:01 PM | markets.businessinsider.comOptimistic Outlook for Vaxcyte’s Market Dominance and High Valuation PotentialJuly 24 at 8:21 AM | americanbankingnews.comAndrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockJuly 23 at 4:56 PM | markets.businessinsider.comJefferies Keeps Their Buy Rating on Vaxcyte (PCVX)July 18, 2024 | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) SVP Elvia Cowan Sells 5,000 SharesJuly 2, 2024 | globenewswire.comVaxcyte Appoints John Furey to Board of DirectorsMay 10, 2024 | finance.yahoo.comVaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational OverviewMay 10, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Vaxcyte Amid Financial Discipline and Promising Vaccine TrialsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Vaxcyte Amid Promising Pipeline and Clear MilestonesSee More Headlines Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCVX CUSIPN/A CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$78.50 High Stock Price Target$95.00 Low Stock Price Target$69.00 Potential Upside/Downside-6.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-402,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.83% Return on Assets-26.89% Debt Debt-to-Equity RatioN/A Current Ratio17.42 Quick Ratio17.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book6.45Miscellaneous Outstanding Shares108,790,000Free Float105,422,000Market Cap$9.14 billion OptionableOptionable Beta0.97 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Grant E. Pickering M.B.A. (Age 56)Co-Founder, CEO & Director Comp: $1.13MMr. Andrew L. Guggenhime M.B.A. (Age 56)President & CFO Comp: $820.81kMr. James Wassil M.B.A. (Age 55)M.S., Executive VP & COO Comp: $521.05kMr. Mikhail Eydelman J.D. (Age 42)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $684.62kDr. Ashish Khanna M.B.A. (Age 52)Ph.D., Co-Founder Dr. Jeff Fairman Ph.D. (Age 60)Co-Founder & VP of Research Ms. Elvia Cowan (Age 51)Senior VP of Finance & Principal Accounting Officer Ms. Janet GraesserSenior Vice President of Corporate Communications & Investor RelationsMs. Whitney JonesChief People OfficerMr. Paul W. Sauer M.B.A. (Age 63)Senior Vice President of Process Development & Manufacturing Comp: $608.96kMore ExecutivesKey CompetitorsForma TherapeuticsNASDAQ:FMTXScholar RockNASDAQ:SRRKEditas MedicineNASDAQ:EDITAdverum BiotechnologiesNASDAQ:ADVMSangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 56,054 shares on 7/26/2024Ownership: 0.431%Allspring Global Investments Holdings LLCBought 296,164 shares on 7/26/2024Ownership: 0.316%EFG Asset Management North America Corp.Bought 11,017 shares on 7/26/2024Ownership: 0.028%Legato Capital Management LLCBought 3,010 shares on 7/26/2024Ownership: 0.010%Bank Pictet & Cie Europe AGSold 952 shares on 7/25/2024Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $62.80 at the start of the year. Since then, PCVX stock has increased by 33.8% and is now trading at $84.05. View the best growth stocks for 2024 here. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.13) by $0.28. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an initial public offering on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI served as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's top institutional shareholders include Bank of New York Mellon Corp (0.43%), Allspring Global Investments Holdings LLC (0.32%), Raymond James & Associates (0.06%) and Banque Pictet & Cie SA (0.05%). Insiders that own company stock include Grant Pickering, Jeff Fairman, Jim Wassil, Andrew Guggenhime, Mikhail Eydelman, Paul Sauer, Elvia Cowan, Halley E Gilbert, Heath Lukatch and Jane Wright-Mitchell. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM) and Riot Platforms (RIOT). This page (NASDAQ:PCVX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCVX Stock Alerts